TrialJournal for immunotherapy of cancer2025

Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1.

Gary Middleton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.